As if I wrote for the journal... BooDog Mo

Quote:

---

BooDog Monday, 03/26/18 08:14:12 AM
Re: Amatuer17 post# 222404 0
Post # of 222410



New FIRST in class for Brilacidin, yes. Go fish.

Possible breakthrough designation coming as well.

Best of luck to all $IPIX longs.

A lot of good things are about to happen with our little IPIX. And the pace of when they start happening can progress very quickly.

Maybe you're familiar with this....

Journal of Pharmacogenomics &
Pharmacoproteomics Ali et al., J Pharmacogenomics Pharmacoproteomics
2017, 8:2
DOI: 10.4172/ 2153-0645.1000171

Newer carbapenems: Doripenem, Imipenem/MK-7655, Brilacidin,
MX-2401 (lipopeptide antibiotic), OP0595 (a new diazabicyclooctane),
Quinolones, Macrocyclic antibiotics, Pleuromutilin, Glycocycline,
Ketolides, Lipopeptides, Iciaprim, Oxazolidinone.


Brilacidin (PMX-30063)
Actively ruptures the bacterial cell membrane structures in gramnegative
enteric bacteria [17].

17. Boucher HW, Talbot GH, Benjamin DK, Bradley J, Guidos RJ, et al.
(2013) 10×'20 progress-development of new drugs active against gramnegative
bacilli: an update from the Infectious Diseases Society of
America. Clin Infect Dis 56: 1685-1694.


https://www.omicsonline.org/open-access/modes...000171.pdf






Quote:
Message in reply to:

Do you see any article, any mention of B as a new class of ABX?
Absolutely not

Does the scientific community talking about it as new MOA ABX - no

That is my point

---